首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1521391

全球抗高血壓藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Antihypertensive Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球抗高血壓藥物市場需求預計將從 2023 年的 375.6 億美元達到近 515.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 3.59%。

抗高血壓藥物是用來控制和降低高血壓的藥物。抗高血壓藥物是用來控制高血壓的藥物，高血壓會增加中風、心臟病和腎衰竭的可能性。這些藥物依其作用機轉分為幾類，包括利尿劑、BETA-阻斷劑、鈣通道阻斷劑、α-阻斷劑、血管張力素 II 受體阻斷劑 (ARB) 和 ACE 抑制劑。每個類別針對血壓調節的不同方面，例如減少血液容量、放鬆血管或降低心率。使用這些藥物有效管理高血壓可以顯著降低心血管事件的風險並改善長期健康結果。

市場動態

全球高血壓盛行率上升是推動抗高血壓藥物需求的主要因素。生活方式的改變，例如不健康食品的消費增加、久坐的習慣和壓力，導致高血壓發病率升高，特別是在城市地區。藥物研究的進步導致了新型抗高血壓藥物的開發，這些藥物具有更高的療效和更少的副作用，從而提高了患者的依從性和結果。此外，人們對與血壓失控相關的健康風險的認知不斷提高，促使更多的人尋求醫療干預，從而促進了市場的成長。旨在早期高血壓檢測和管理的政府措施和公共衛生運動也有助於市場成長。人口老化更容易患高血壓，這進一步推動了對有效抗高血壓治療的需求。醫療保健支出的增加以及這些藥物在發展中地區的供應量的增加預計將擴大市場範圍。此外，研究機構和製藥公司之間合作開發創新的治療方案創造了新的市場機會。然而，與長期使用抗高血壓藥物和患者不依從性相關的副作用可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球抗高血壓藥物市場的各個細分市場進行了包容性評估。抗高血壓藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

抗高血壓藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按治療類型

利尿劑
血管緊張素轉換酶抑制劑
血管張力素受體阻斷劑
BETA-受體阻斷劑
血管擴張劑
鈣通道阻斷劑
腎素抑制劑
α-阻斷劑
其他

按類型

原發性高血壓
繼發性高血壓

依藥物類型

單一療法
聯合療法
固定劑量組合

按配銷通路

零售藥局
醫院藥房
網路藥局
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲抗高血壓藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。抗高血壓藥物市場的主要參與者包括輝瑞公司、賽諾菲公司、諾華公司、勃林格殷格翰有限公司、Actelion Ltd.、霍夫曼-拉羅氏有限公司、拜耳股份公司、第一三共株式會社、武田藥品工業株式會社。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按治療類型分類的市場吸引力分析
- 按類型分類的市場吸引力分析
- 按藥物類型分類的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球抗高血壓藥物市場分析：依治療類型

按治療類型概述
按治療類型進行歷史和預測數據分析
利尿劑
血管緊張素轉換酶抑制劑
血管張力素受體阻斷劑
BETA-受體阻斷劑
血管擴張劑
鈣通道阻斷劑
腎素抑制劑
α-阻斷劑
其他

第 6 章：全球抗高血壓藥物市場分析：按類型

按類型概述
按類型分析歷史和預測數據
原發性高血壓
繼發性高血壓

第 7 章：全球抗高血壓藥物市場分析：按藥物類型

按藥物類型概述
按藥物類型進行歷史和預測數據分析
單一療法
聯合療法
固定劑量組合

第 8 章：全球抗高血壓藥物市場分析：按分銷管道

配銷通路概述
按配銷通路進行歷史和預測資料分析
零售藥局
醫院藥房
網路藥局
其他

第 9 章：全球抗高血壓藥物市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：抗高血壓藥物公司的競爭格局

降血壓藥市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi SA

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Boehringer Ingelheim GmbH

公司簡介
公司收入
產品
最近的發展

Actelion Ltd.

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Daiichi Sankyo Company Limited

公司簡介
公司收入
產品
最近的發展

Takeda Pharmaceutical Company Limited

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115233

The global demand for Antihypertensive Drugs Market is presumed to reach the market size of nearly USD 51.59 Billion by 2032 from USD 37.56 Billion in 2023 with a CAGR of 3.59% under the study period 2024-2032.

Antihypertensive drugs are medications prescribed to control and lower high blood pressure. Antihypertensive drugs are medications prescribed to manage high blood pressure (hypertension), a condition that raises the likelihood of stroke, heart disease, and kidney failure. These drugs are categorized into several classes based on their mechanisms of action, including diuretics, beta-blockers, calcium channel blockers, alpha-blockers, angiotensin II receptor blockers (ARBs), and ACE inhibitors. Each class targets different aspects of blood pressure regulation, such as reducing blood volume, relaxing blood vessels, or decreasing heart rate. Effective management of hypertension with these drugs can significantly lower the risk of cardiovascular events & improve long-term health outcomes.

MARKET DYNAMICS

The rising prevalence of hypertension globally is a primary factor driving the demand for antihypertensive drugs. Lifestyle changes, such as increased consumption of unhealthy foods, sedentary habits, and stress, have led to a higher incidence of hypertension, particularly in urban areas. Advances in pharmaceutical research have led to the development of new classes of antihypertensive drugs with improved efficacy and fewer side effects, enhancing patient compliance and outcomes. Additionally, the rising awareness about the health risks associated with uncontrolled blood pressure has prompted more individuals to seek medical intervention, increasing the market growth. Government initiatives and public health campaigns aimed at early hypertension detection and management also contribute to market growth. The aging population, which is more susceptible to hypertension, further drives the need for effective antihypertensive therapies. Rising healthcare expenditures and the increasing availability of these drugs in developing regions are expected to expand market reach. Furthermore, collaboration between research institutions and pharmaceutical companies to develop innovative treatment options creates new market opportunities. However, the side effects associated with prolonged use of antihypertensive drugs and patient non-compliance may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antihypertensive Drugs. The growth and trends of Antihypertensive Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antihypertensive Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

Diuretics
Angiotensin Converting Enzyme Inhibitors
Angiotensin Receptor Blockers
Beta-blockers
Vasodilators
Calcium Channel Blockers
Renin Inhibitors
Alpha-Blockers
Others

By Type

Primary Hypertension
Secondary Hypertension

By Medication Type

Monotherapy
Combination Therapy
Fixed Dose Combinations

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antihypertensive Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antihypertensive Drugs market include Pfizer Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ANTIHYPERTENSIVE DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Medication Type
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY THERAPY TYPE

5.1. Overview By Therapy Type
5.2. Historical and Forecast Data Analysis By Therapy Type
5.3. Diuretics Historic and Forecast Sales By Regions
5.4. Angiotensin Converting Enzyme Inhibitors Historic and Forecast Sales By Regions
5.5. Angiotensin Receptor Blockers Historic and Forecast Sales By Regions
5.6. Beta-blockers Historic and Forecast Sales By Regions
5.7. Vasodilators Historic and Forecast Sales By Regions
5.8. Calcium Channel Blockers Historic and Forecast Sales By Regions
5.9. Renin Inhibitors Historic and Forecast Sales By Regions
5.10. Alpha-Blockers Historic and Forecast Sales By Regions
5.11. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY TYPE

6.1. Overview By Type
6.2. Historical and Forecast Data Analysis By Type
6.3. Primary Hypertension Historic and Forecast Sales By Regions
6.4. Secondary Hypertension Historic and Forecast Sales By Regions

7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY MEDICATION TYPE

7.1. Overview By Medication Type
7.2. Historical and Forecast Data Analysis By Medication Type
7.3. Monotherapy Historic and Forecast Sales By Regions
7.4. Combination Therapy Historic and Forecast Sales By Regions
7.5. Fixed Dose Combinations Historic and Forecast Sales By Regions

8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Retail Pharmacies Historic and Forecast Sales By Regions
8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
8.5. Online Pharmacies Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIHYPERTENSIVE DRUGS COMPANIES

10.1. Antihypertensive Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ANTIHYPERTENSIVE DRUGS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Pfizer Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Sanofi S.A
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Novartis AG
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Boehringer Ingelheim GmbH
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Actelion Ltd.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. F. Hoffmann-La Roche Ltd.
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Bayer AG
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Daiichi Sankyo Company Limited
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Takeda Pharmaceutical Company Limited
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments